{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-26-000074","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2026-06-15T20:12:31+00:00","discovered_at":"2026-06-15T20:13:00.324961+00:00","generated_at":"2026-06-15T20:18:48.895544+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Immuneering appoints Andrew Gengos as CFO, effective July 16, 2026","bullets":["Andrew Gengos named CFO and Treasurer, replacing Mallory Morales who remains SVP Finance, CAO.","Gengos gets base salary of $530,000 and target bonus of 40% of base salary.","Inducement grant of 650,000 stock options under 2025 Employment Inducement Award Plan.","Gengos previously CFO at Terns Pharmaceuticals (Feb 2025-May 2026) and CFO/CBO at LeonaBio.","Gengos' employment includes severance provisions: 12 months salary plus COBRA on qualifying termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-26-000074","json":"https://secwatch.observer/filing/0001790340-26-000074.json","markdown":"https://secwatch.observer/filing/0001790340-26-000074.md","text":"https://secwatch.observer/filing/0001790340-26-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000074/0001790340-26-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000074/imrx-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:18:48.895544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"292fb5ebe6","claim":"Andrew Gengos was appointed as Chief Financial Officer and Treasurer at Immuneering Corp.","evidence_excerpt":"On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the date Mr. Gengos actually commences employment with the Company, the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000074/0001790340-26-000074-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"9ac1f452a5","claim":"Mallory Morales changed role as Senior Vice President Finance, Chief Accounting Officer at Immuneering Corp.","evidence_excerpt":"The Board also designated Mr. Gengos as the Company’s principal financial officer as of the Effective Date, succeeding Mallory Morales in such role. In her ongoing role as Senior Vice President Finance, Chief Accounting Officer, Ms. Morales will continue to serve as the Company’s principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000074/0001790340-26-000074-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"succeeded as principal financial officer, remains SVP Finance, CAO"},{"label":"Role","value":"Senior Vice President Finance, Chief Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}